Elligo expands its Research Ready network and adds its first oncology practice through a partnership with Austin Cancer Center, which is currently enrolling patients for breast cancer studies.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Panelist during the opening session of the DIA Annual Meeting last week stressed the need to work collaboratively, bringing patients into the fold as co-creators of clinical trials to ‘create a whole new landscape for research.’
Datavant enters partnership with Prognos to expand the latter’s analytics capabilities to determine clinical outcomes and inform decision making as data availability grows.
Iqvia today launched a new “patient centered endpoints” solution, which captures the patient experience during clinical trials and real world studies, says SVP.
CRF Bracket – newly-rebranded as Signant Health – is looking to build momentum around eConsent, rethink the patient’s connection to the supply chain, and build out a stronger analytics platform, says CEO.
Analytical software provider and CRO, Cytel, and biostatistics company, Axio Research, merge to deliver analytical solutions for clinical research drug development challenges.
Females as caregivers, clinical trial participants, and biopharma leaders are among the different roles to be carefully considered as the industry aims for increased inclusion, says BBK executive.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Parexel forms a strategic partnership with Clariness to deploy the ClinLife platform in the Greater China area as the CRO looks to recruit and engage patients in their native language and via social media channels.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
